Mehmet Ali Nahit Sendur

In patients with stage III dMMR colon cancer: Adding atezolizumab to mFOLFOX6 significantly improved 3-year disease-free survival (86%🆚76%). Immunotherapy continues to reshape our approach. @NEJM @OncoAlert @ONCOassist

sac-TMT+pembro in 1st line UC shows ⬆️⬆️ efficacy (Fudan Uni 🇨🇳) . It’s a TROP2/TOPO1 ADC but efficacy looks different from SG or D-DXD @scocmem In 1st line UC it has 68% ORR , 1yr PFS & 80% 12 month OS. 60% TRAEs,13% tox discontinuations. This mono and combo requires further exploration. @OncoAlert

Perioperative MIBC is entering a new era. The question is no longer if. It is which regimen, for which patient. #gu26 #cancer #oncology #ASCO @oncoalert @ASCO @yekeduz_emre @CParkMD @OncBrothers @Larvol @nataliagandur @crisbergerot @ONCOassist @IMG_Oncologists

🎯 #IGICC | Managing biomarker-negative metastatic gastric cancer remains challenging. Dr. Mehmet Ali Nahit Sendur @nahit_sendur reviews first-line doublet chemotherapy standards, the limited role of triplet regimens, and evolving second-line strategies including ramucirumab-based therapy and IO in later lines. 🎥 Watch on #Vumedi: tinyurl.com/yu9wrfj6 #GastricCancer #GIOncology #CancerTreatment

3 studies testing Perioperative immune bases therapy (EVP or Gem/Cis/Durva) in muscle invasive bladder all have shown an OS advantage vs standard of care. KN905 (EVP) is distinct in that it’s in a cisplatin ineligible population (accounting for the poor performance of the control arm). It’s also a smaller trial. The control arm of KN-B15 performed slightly better than NIAGARA (Gem/cis for both), but the trials are otherwise similar. The pCR in the EVP trails and the consistent efficacy of EVP is striking. #GU26

KN-B15/EV303: R3 Perioperative EVP vs Gem/cis in MIBC shows EFS HR 0.53 (0.41–0.70), OS HR 0.65 (0.48-0.89), pCR 56% vs 33%, G3+ tox 76% vs 67% #GU26. About half the patients completed 9 cycles of EVP. These are great results. Gem/cid is harder to beat when not all patients are at risk of relapse. Bladder sparing approaches for cCR (~60%) will be where this ends. ‘EVP 1st, ask questions later’. These studies are needed soon.

Çok önemli, tarihi bir gelişme. Yıllarca p53 için “ilaçlar için hedeflenemez” denildi. Kanser gelişiminde çok önemli bir gen!🧬 Belki artık bu cümleyi yeniden düşünme zamanı. NEJM’de yayımlanan faz 1 çalışmada,TP53 Y220C mutasyonunu hedefleyen rezatapopt ile ümit veren sonuçlar. Henüz bir dönüm noktası değil. Ama şunu gösteriyor: Doğru biyolojiyi anladığımızda, “imkânsız” dediğimiz kapılar aralanabiliyor. @NEJM

Erkeklerde kanserlerin %45’i, Kadınlarda %30’u önlenebilir. @saglikbakanligi @WHO_Turkiye @WHO @DrTedros #WorldCancerDay

Farelerde kanseri iyileştirmek her hafta manşet olan akademik bir başarıdır, ancak insanın biyolojik labirentinde bu başarıların %90'ı sessizce kaybolur. Barbacid’in talep ettiği 30 milyon €, bir ilacın gerçek dünyaya ulaşması için gereken milyon dolarlık okyanusta sadece küçük bir damladır. Pazarlama🆚Bilim arasındaki gerilim, onkoloji dünyasında sadece bir iletişim sorunu değil, aynı zamanda etik bir yol ayrımıdır. Bilim, doğası gereği şüpheci ve sabırlıdır; her yeni veriyi en sert testlerden geçirerek doğrulamaya odaklanır. Pazarlama ise bu sürecin içindeki küçük bir başarıyı alıp, onu "mucize" veya "devrim" etiketiyle bir umut ürününe dönüştürerek satışa sunar. Bizim görevimiz insanlara sadece duymak istediklerini söylemek değil; karmaşayı sadeleştirerek, güven veren bir gerçekliğin huzurunu hissettirmektir. #pankreas #kanser

PATINA: Adding palbociclib to maintenance anti-HER2 + endocrine therapy improved PFS in HR+/HER2+ Met. Breats Cancser (44.3 vs 29.1 mo). More toxicity, mainly neutropenia. @NEJM @OncoAlert @AnnPartridgeMD @DrEricWiner @StoverLab @LoiSher @BreastCancerNow

In mice, pairing daraxonrasib with afatinib and a STAT3 degrader erased tumors and kept them away for 200+ days, with good tolerance. Promising and hopeful results for pancreatic cancer by Mariano Barbacid and team! But mouse “cures” need human proof. @CNIOStopCancer @PNASNews @OncoAlert

This is the table we’ve used (common AEs, black📦warnings, & dose⬇️) during our ToxCheck 🗣️ on ADCs in #LungCancer with @sands_jacob: 1. TDXd: 🫁, Nausea, fatigue 2. DatoDXd: Stomatitis, dry 👀, 🫁 3. TelisoV: Neuropathy #OncTwitter #MedTwitter #lcsm @OncoAlert @OncUpdates

For the first time, a CDK4/6 inhibitor shows a statistically significant and clinically meaningful OS benefit in the adjuvant setting. Adj CDK4/6 inh in HR+/HER2– early breast cancer is here to stay — but not for everyone. Both monarchE (abemaciclib, 7-year OS benefit) and NATALEE (ribociclib, 5-year iDFS benefit) have reshaped the adjuvant landscape. ✅ monarchE: HR for OS 0.84; sustained IDFS/DRFS gains → early micrometastatic suppression with a durable carry-over effect. ✅ NATALEE: HR for iDFS 0.71; broader inclusion (N0–N+), lower dose (400 mg × 3 years), favorable tolerability. Yet, these are not “treat-all” signals. 🔹 The absolute benefit remains modest for lower-risk or node-negative cases. 🔹 Long-term toxicity, adherence, and cost-effectiveness data will define real-world value. Bottom line: Adj CDK4/6 inhibition should be selective, not universal — guided by pathological risk, biology, and patient preference. #ESMO25 #BreastCancer #Abemaciclib #monarchE #CDK46 #Oncology #ClinicalResearch

The final analysis of cabozantinib plus nivolumab in 1st line clear cell renal cancer @Annals_Oncology @DrChoueiri shows consistent data over time and with other VEGF/PD-1 combinations. ‘Pick one and use it well’ remains a good approach.

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer buff.ly/sNLjXdf This phase 3 trial evaluating first-line treatment for HER2-positive advanced or metastatic #BreastCancer , trastuzumab deruxtecan plus pertuzumab significantly improved outcomes compared with the standard regimen of a taxane, trastuzumab, and pertuzumab (THP). Among previously untreated patients, median progression-free survival was 40.7 months with trastuzumab deruxtecan plus pertuzumab versus 26.9 months with THP (hazard ratio, 0.56; P<0.00001), and confirmed responses were more frequent and durable (85.1% vs. 78.6%; median duration of response 39.2 vs. 26.4 months). Safety findings were consistent with known profiles, though interstitial lung disease or pneumonitis occurred more often with trastuzumab deruxtecan (12.1% vs. 1.0%). Overall, the combination of trastuzumab deruxtecan and pertuzumab yielded a substantial progression-free survival benefit without new safety concerns, supporting its potential as a new first-line standard for HER2-positive metastatic breast cancer. @stolaney1 @DrRBarroso @mfrimawi @ToiMasakazu @nahit_sendur @mlcasalnuovo @LoiblSibylle @matteolambe @aftimosp @E_de_Azambuja @DrSGraff @jesusanampa @ErikaHamilton9 @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @hoperugo @teamoncology @LoiSher @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @MammaMiaMagazin #OncoAlertAF @nataliagandur @acampsmalea @BRicciutiMD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK @MarioBalsaMD @DrMirallas @GIMedOnc @OscarTahuahua @UOzkerim @DrRishabhOnco @Onco_Cifu88

9 Breast Ca studies that we touched on with @VKaklamani for #ESMO25: ✅ #monarchE & #NATALEE ✅ #VIKTORIA1 ✅ #evERA ✅ #DESTINYBreast: 05/09/11 ✅ #ASCENT03 ✅ #TropionBreast02 #OncTwitter #MedTwitter @OncUpdates @myESMO @OncoAlert

Disitamab vedotin + toripalimab doubles survival benefit vs chemo in HER2+ urothelial carcinoma. Median OS: 31.5 vs 16.9 mo (HR 0.54). @TeresaSAmaral @E_de_Azambuja @JyotiBajpai01 @ArBayle @Ecastromarcos @GillSharlene @PGrivasMDPhD @ErikaHamilton9 @DrAngelaLamarca @DrJonLim @StephenVLiu @LoiSher @DrJNaidoo @NReguart @LorenzaRimassa @Rodrosb @LizzySmyth1 @pawel_sobczuk @PTarantinoMD @darioT_ @ArndtVogel @TiansterZhang #ESMOAmbassadors #ESMO25 @neerajaiims @yekeduz_emre @tompowles1 @OncoAlert @ONCOassist @OncBrothers @dmukherji @curijoey @DrChoueiri

DESTINY-Breast11: Neoadjuvant T-DXd + THP improves pCR by 11.2% vs ddAC-THP in HER2+ early breast cancer! A step closer to redefining HER2-positive neoadjuvant therapy. #ESMO25 #BreastCancer @TeresaSAmaral @E_de_Azambuja @JyotiBajpai01 @ArBayle @Ecastromarcos @GillSharlene @PGrivasMDPhD @ErikaHamilton9 @DrAngelaLamarca @DrJonLim @StephenVLiu @LoiSher @DrJNaidoo @NReguart @LorenzaRimassa @Rodrosb @LizzySmyth1 @pawel_sobczuk @PTarantinoMD @darioT_ @ArndtVogel @TiansterZhang #ESMOAmbassadors #ESMO25 @neerajaiims @yekeduz_emre @tompowles1 @OncoAlert @ONCOassist @OncBrothers @dmukherji @curijoey @DrChoueiri

One week to #ESMO25. An unprecedented ESMO conference. Seven positive press releases, anticipating the expansion of T-DXd to the curative setting, two Trop2 ADCs reaching first-line mTNBC, 2 novel ET-based combos, adjuvant CDK4/6i improving OS. See you in Berlin! #ESMOAmbassadors

🔥 Breakthrough in extensive-stage small-cell lung cancer maintenance! 🫁Lurbinectedin + Atezolizumab doubled PFS vs Atezolizumab alone! 🫁OS benefit also significant (13.2 vs 10.6 mo) 💥 First phase 3 trial to improve both PFS & OS in 1L maintenance for ES-SCLC. @OncoAlert @TheLancet @IASLC @ASCO #ASCO25 @OncBrothers thelancet.com/journals/lance…